転移性去勢抵抗性前立腺癌患者を対象としたパストリタミグ+ドセタキセルとドセタキセルの比較試験 (KLK2-PASenger)
第3相無作為化非盲検試験:ヒトカリクレイン2を標的とするT細胞再指向性薬剤パストリタミグ(JNJ-78278343)+ドセタキセル対ドセタキセルによる転移性去勢抵抗性前立腺癌治療
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85225
- 募集
- Arizona Clinical Trials
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72211
- 募集
- Arkansas Urology
-
Springdale、Arkansas、アメリカ、72762
- 募集
- Highlands Oncology Group
-
-
California
-
Fountain Valley、California、アメリカ、92708
- 募集
- MemorialCare Orange Coast Medical Center
-
La Jolla、California、アメリカ、92037
- 募集
- University Of California San Diego
-
Los Alamitos、California、アメリカ、90720
- 募集
- Cancer and Blood Specialty Clinic
-
Los Angeles、California、アメリカ、90033
- 募集
- USC Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90095
- 募集
- Ronald Reagan UCLA Medical Center
-
Los Angeles、California、アメリカ、90067
- 募集
- Valkyrie Clinical Trials
-
Riverside、California、アメリカ、92505
- 募集
- Kaiser Permanente Southern California
-
San Diego、California、アメリカ、92123
- 募集
- Sharp Center for Research
-
Santa Monica、California、アメリカ、90404
- 募集
- Providence Saint John s Health Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- 募集
- Rocky Mountain Cancer Centers
-
Denver、Colorado、アメリカ、80210
- 募集
- AdventHealth Porter Oncology Research
-
Edwards、Colorado、アメリカ、81632
- 募集
- Vail Health Shaw Cancer Center
-
Grand Junction、Colorado、アメリカ、81505
- 募集
- Grand Valley Oncology
-
Lakewood、Colorado、アメリカ、80228
- 募集
- Colorado Clinical Research
-
-
Florida
-
Orlando、Florida、アメリカ、32803
- 募集
- AdventHealth Orlando
-
Pembroke Pines、Florida、アメリカ、33026
- 募集
- Memorial Cancer Institute
-
Sarasota、Florida、アメリカ、34232
- 募集
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Winship Cancer Institute Emory University
-
-
Illinois
-
Lisle、Illinois、アメリカ、60532
- 募集
- Duly Health and Care
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- 募集
- Cancer Center of Kansas Heritage Plaza Medical Building
-
-
Kentucky
-
Edgewood、Kentucky、アメリカ、41017
- 募集
- St Elizabeth Healthcare
-
Louisville、Kentucky、アメリカ、40207
- 募集
- Norton Cancer Institute
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- 募集
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Johns Hopkins Hospital
-
Baltimore、Maryland、アメリカ、21201
- 募集
- University of Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Johns Hopkins Medical Institutions
-
Bethesda、Maryland、アメリカ、20817
- 募集
- Center for Cancer and Blood Disorders
-
Towson、Maryland、アメリカ、21204
- 募集
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General
-
-
Michigan
-
Sterling Heights、Michigan、アメリカ、48314
- 募集
- Profound Research LLC at Cancer and Leukemia Center
-
-
Minnesota
-
Saint Louis Park、Minnesota、アメリカ、55426
- 募集
- HealthPartners Frauenshuh Cancer Center CRC West
-
Saint Paul、Minnesota、アメリカ、55101
- 募集
- HealthPartners Cancer Center at Regions Hospital CRC East
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- 募集
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68506
- 募集
- NHO Revive Research Institute, LLC
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- 募集
- Cooper Health System MD Anderson Cancer Center at Cooper
-
East Brunswick、New Jersey、アメリカ、08816
- 募集
- Astera Cancer Care
-
New Brunswick、New Jersey、アメリカ、08901
- 募集
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola、New York、アメリカ、11501
- 募集
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Medical Center
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- 募集
- Gabrail Cancer Center
-
Cincinnati、Ohio、アメリカ、45219
- 募集
- University of Cincinnati
-
Cleveland、Ohio、アメリカ、44109
- 募集
- Metrohealth Medical Center
-
-
Oregon
-
Springfield、Oregon、アメリカ、97477
- 募集
- Oregon Urology Institute
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- 募集
- Lehigh Valley Hospital
-
Bala-Cynwyd、Pennsylvania、アメリカ、19004
- 募集
- MidLantic Urology
-
Hershey、Pennsylvania、アメリカ、17033
- 募集
- Penn State Milton S. Hershey Medical Center
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach、South Carolina、アメリカ、29572
- 募集
- Carolina Urologic Research Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- 募集
- Avera Medical Group
-
Watertown、South Dakota、アメリカ、57201
- 募集
- Prairie Lakes Health Care System
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37909
- 募集
- Tennessee Cancer Specialists
-
-
Texas
-
Austin、Texas、アメリカ、78731
- 募集
- Texas Oncology
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern Medical Center
-
Houston、Texas、アメリカ、77027
- 募集
- Houston Metro Urology
-
Sugar Land、Texas、アメリカ、77479
- 募集
- Texas Oncology 1
-
The Woodlands、Texas、アメリカ、77380
- 募集
- Renovatio Clinical
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Research Center
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutch Cancer Center Sloan Clinic 2
-
-
-
-
-
Cardiff、イギリス、CF14 2TL
- 募集
- Velindre Cancer Centre
-
Glasgow、イギリス、G12 0YN
- 募集
- Beatson West Of Scotland Cancer Centre
-
London、イギリス、EC1A 7BE
- 募集
- St Bartholomews Hospital
-
London、イギリス、SW3 6JJ
- 募集
- The Royal Marsden NHS Trust
-
Newcastle upon Tyne、イギリス、NE7 7DN
- 募集
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Preston、イギリス、PR2 9HT
- 募集
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
Sutton、イギリス、SM2 5PT
- 募集
- Royal Marsden Hospital
-
-
-
-
-
Florence、イタリア、50134
- 募集
- Azienda Ospedaliero Universitaria Careggi
-
Localita La Schiana Pozzuoli、イタリア、80078
- 募集
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Milan、イタリア、20141
- 募集
- Istituto Europeo di Oncologia
-
Milan、イタリア、20132
- 募集
- IRCCS Ospedale San Raffaele
-
Roma、イタリア、00144
- 募集
- Istituto Nazionale Tumori Regina Elena
-
Torino、イタリア、10126
- 募集
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Heidelberg、オーストラリア、3084
- 募集
- Warringal Private Hospital
-
Kurralta Park、オーストラリア、5037
- 募集
- Icon Cancer Centre Kurralta Park
-
Melbourne、オーストラリア、3000
- 募集
- Peter MacCallum Cancer Centre
-
Wahroonga、オーストラリア、2076
- 募集
- Sydney Adventist Hospital
-
Woolloongabba、オーストラリア、4102
- 募集
- Princess Alexandra Hospital
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z4E6
- 募集
- British Columbia Cancer Agency
-
Victoria、British Columbia、カナダ、V8R 6V5
- 募集
- British Columbia Cancer Agency Vancouver Island Centre
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- The Ottawa Hospital Cancer Centre
-
Toronto、Ontario、カナダ、M5G 2C4
- 募集
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 0A9
- 募集
- Centre de Recherche du CHUM
-
Québec、Quebec、カナダ、G1R 2J6
- 募集
- CHU de Quebec Universite Laval
-
-
-
-
-
Badalona、スペイン、08916
- 募集
- Hosp. Univ. Germans Trias I Pujol
-
Madrid、スペイン、28034
- 募集
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28041
- 募集
- Hosp. Univ. 12 de Octubre
-
Murcia、スペイン、30008
- 募集
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Seville、スペイン、41009
- 募集
- Hosp. Virgen Macarena
-
Valencia、スペイン、46014
- 募集
- Hosp. Gral. Univ. Valencia
-
Zaragoza、スペイン、50009
- 募集
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Adana、トルコ(Türkiye)、01170
- 募集
- Adana City Hospital
-
Ankara、トルコ(Türkiye)、06010
- 募集
- Gulhane Training and Research Hospital
-
Ankara、トルコ(Türkiye)、06100
- 募集
- Ankara University Medical Faculty
-
Istanbul、トルコ(Türkiye)、34096
- 募集
- Istanbul University Cerrahpasa tip Fakultesi
-
Istanbul、トルコ(Türkiye)、34147
- 募集
- Koc Universitesi Hastanesi
-
Izmir、トルコ(Türkiye)、35170
- 募集
- Medicana International Izmir
-
-
-
-
-
Dresden、ドイツ、01307
- 募集
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg、ドイツ、47169
- 募集
- Urologicum Duisburg
-
Essen、ドイツ、45147
- 募集
- Universitaetsklinikum Essen
-
Hamburg、ドイツ、20246
- 募集
- Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
-
München、ドイツ、81675
- 募集
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Nürtingen、ドイツ、72622
- 募集
- Studienpraxis Urologie Drs. Feyerabend
-
-
-
-
-
Bordeaux、フランス、33076
- 募集
- Institut Bergonie
-
Clermont-Ferrand、フランス、63011
- 募集
- Centre Jean Perrin
-
Lille、フランス、59000
- 募集
- Centre Oscar Lambret
-
Lyon、フランス、69008
- 募集
- Centre Leon Berard
-
Nîmes、フランス、30900
- 募集
- Groupe Hospitalo-Universitaire Carémeau
-
Paris、フランス、75908
- 募集
- Hopital Europeen Georges-Pompidou
-
Rennes、フランス、35062
- 募集
- Centre Eugene Marquis
-
Villejuif、フランス、94800
- 募集
- Gustave Roussy
-
-
-
-
-
Bauru、ブラジル、17033-495
- 募集
- NAIC Nair Antunes Instituto do Cancer
-
Natal、ブラジル、59062 000
- 募集
- Liga Norte Riograndense Contra O Cancer
-
Santa Cruz do Sul、ブラジル、96835-100
- 募集
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André、ブラジル、09060 870
- 募集
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo、ブラジル、01243 020
- 募集
- Hospital Samaritano de Sao Paulo
-
-
-
-
-
San Juan、プエルトリコ、935
- 募集
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Aalst、ベルギー、9300
- 募集
- AZORG campus Aalst Moorselbaan
-
Antwerp、ベルギー、2610
- 募集
- ZAS Augustinus
-
Ghent、ベルギー、9000
- 募集
- AZ Maria Middelares
-
La Louvière、ベルギー、7100
- 募集
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège、ベルギー、4000
- 募集
- CHC MontLegia
-
-
-
-
-
Kota Kinabalu、マレーシア、88996
- 募集
- Hospital Wanita dan Kanak-Kanak Sabah
-
Kuala Lumpur、マレーシア、59100
- 募集
- University Malaya Medical Centre
-
Kuala Lumpur、マレーシア、50586
- 募集
- Hospital Kuala Lumpur
-
Kuala Lumpur、マレーシア、59100
- 募集
- Pantai Hospital Kuala Lumpur
-
Kuching、マレーシア、93586
- 募集
- Hospital Umum Sarawak
-
-
-
-
-
Beijing、中国、100142
- 募集
- Beijing Cancer Hospital
-
Beijing、中国、100034
- 募集
- Peking University First Hospital
-
Beijing、中国、101100
- 募集
- Beijing Luhe Hospital, Capital Medical University
-
Chengdu、中国、610014
- 募集
- The Third People's Hospital of Chengdu
-
Chengdu、中国、610041
- 募集
- West China Hospital Sichuan University
-
Chongqing、中国、400030
- 募集
- Chongqing University Cancer Hospital
-
Guangzhou、中国、510120
- 募集
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou、中国、510060
- 募集
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310009
- 募集
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing、中国、210009
- 募集
- Nanjing Drum Tower Hospital
-
Shanghai、中国、200080
- 募集
- Shanghai General Hospital
-
Shanghai、中国、200031
- 募集
- Huashan Hospital Fudan University
-
Shanghai、中国、200082
- 募集
- Xinhua hospital,Shanghai Jiaotong University
-
Tianjin、中国、300211
- 募集
- The Second Hospital Of Tianjin Medical University
-
Wuhan、中国、430014
- 募集
- The Central Hospital of Wuhan
-
Xi'an、中国、710061
- 募集
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Taichung、台湾、435
- 募集
- Tungs' Taichung MetroHarbor Hospital
-
Taichung、台湾、404
- 募集
- China Medical University Hospital
-
Taichung、台湾、407219
- 募集
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- 募集
- National Cheng Kung University Hospital
-
Taoyuan、台湾、333
- 募集
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Bunkyō City、日本、113 8431
- 募集
- Juntendo University Hospital
-
Hirakata、日本、573-1191
- 募集
- Kansai Medical University Hospital
-
Kanazawa、日本、920 8641
- 募集
- Kanazawa University Hospital
-
Kobe、日本、650 0017
- 募集
- Kobe University Hospital
-
Sagamihara、日本、252-0375
- 募集
- Kitasato University Hospital
-
Sunto Gun、日本、411 8777
- 募集
- Shizuoka Cancer Center
-
Yokohama、日本、232 0024
- 募集
- Yokohama City University Medical Center
-
-
-
-
-
Goyang-si、韓国、10408
- 募集
- National Cancer Center
-
Seoul、韓国、05505
- 募集
- Asan Medical Center
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center
-
Seoul、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06591
- 募集
- The Catholic University of Korea Seoul St Marys Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
- Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion criteria:
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Pasritamig+Docetaxel
Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met. |
Pasritamig will be administered.
他の名前:
Docetaxel will be administered. |
|
アクティブコンパレータ:Docetaxel
Participants will receive docetaxel along with prednisone/prednisolone as background medication. |
Docetaxel will be administered. Prednisone/Prednisolone will be administered. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 1 years 10 months
|
rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first. |
Up to approximately 1 years 10 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to approximately 4 years 5 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 4 years 5 months
|
|
Time to Symptomatic Progression (TSP)
時間枠:Up to approximately 4 years 5 months
|
TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms. |
Up to approximately 4 years 5 months
|
|
Time to Subsequent Therapy (TST)
時間枠:Up to approximately 4 years 5 months
|
TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer |
Up to approximately 4 years 5 months
|
|
Time to Skeletal-Related Event (TSRE)
時間枠:Up to approximately 4 years 5 months
|
TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression. |
Up to approximately 4 years 5 months
|
|
Objective Response Rate (ORR)
時間枠:Up to approximately 4 years 5 months
|
ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR. |
Up to approximately 4 years 5 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 4 years 5 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to approximately 4 years 5 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
時間枠:Up to approximately 4 years 5 months
|
Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
時間枠:Up to approximately 4 years 5 months
|
PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
時間枠:Up to approximately 4 years 5 months
|
PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Duration of PSA Response
時間枠:Baseline and up to approximately 4 years 5 months
|
Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%. |
Baseline and up to approximately 4 years 5 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
時間枠:Up to approximately 4 years 5 months
|
PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first. |
Up to approximately 4 years 5 months
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
時間枠:Up to approximately 4 years 5 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 4 years 5 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
時間枠:Up to approximately 4 years 5 months
|
Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported. |
Up to approximately 4 years 5 months
|
|
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
時間枠:Baseline up to approximately 4 years 5 months
|
The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
時間枠:Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
時間枠:Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
時間枠:Baseline up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life. |
Baseline up to approximately 4 years 5 months
|
|
Time to Sustained Worsening of Pain as Assessed by BPI-SF
時間枠:Up to approximately 4 years 5 months
|
Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Up to approximately 4 years 5 months
|
|
Treatment Side Effect as Assessed by EORTC IL46 Score
時間枠:Up to approximately 4 years 5 months
|
The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much". |
Up to approximately 4 years 5 months
|
|
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
時間枠:Up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life. |
Up to approximately 4 years 5 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 78278343PCR3003
- 2025-522713-29-00 (レジストリ識別子:EUCT number)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。